Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered ... Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The company's drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Show more
The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash...
MINNEAPOLIS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
MINNEAPOLIS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.37 | -21.0362047441 | 16.02 | 16.14 | 11.51 | 419307 | 13.75097421 | CS |
4 | -3.11 | -19.7335025381 | 15.76 | 16.5431 | 11.51 | 255350 | 14.95270193 | CS |
12 | -5.02 | -28.4097340125 | 17.67 | 17.93 | 11.51 | 261992 | 15.07781723 | CS |
26 | -4.11 | -24.522673031 | 16.76 | 19.77 | 11.51 | 324402 | 16.07749199 | CS |
52 | -0.51 | -3.87537993921 | 13.16 | 22.188 | 11.51 | 261542 | 16.28770309 | CS |
156 | -4.13 | -24.6126340882 | 16.78 | 22.188 | 4.81 | 128416 | 14.21752482 | CS |
260 | -0.36 | -2.76710222905 | 13.01 | 33.01 | 4.03 | 108350 | 16.2950061 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.